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Monoclonal antibodies that effectively neutralize HIV-1 have been widely sought, yet few have been isolated.
Now, technological advances in sera evaluation, B cell stimulation, microneutralization, and antibody cloning
have allowed Burton and colleagues to identify two broadly neutralizing monoclonal antibodies, PG9 and
PG16, which provide insights for HIV vaccine design.In the struggle between human immuno-
deficiency virus type 1 (HIV-1) and the
human immune system, the virus often
seems to gain the upper hand. Antibodies
to the viral envelope glycoproteins, gp120
and gp41, are diverted by conformational
flexibility, and key epitopes are masked
by variable loops and N-linked glycosyla-
tion (reviewed in Pantophlet and Burton,
2006; Wyatt and Sodroski, 1998). Indeed,
in the persistent infection that typifies
HIV-1, the virus stays ahead of the
immune system, with neutralizing anti-
bodies against the predominant viral292 Cell Host & Microbe 6, October 22, 2009strain only elicited after several months,
by which time the viral swarm has evolved
sufficiently to escape (Richman et al.,
2003; Wei et al., 2003).
Yet, viral evasion is not perfect. After
several years of infection, sera from a
significant percentage of infected individ-
uals (current estimates range from 15%–
25%) develop antibodies capable of neu-
tralizing a diverse range of HIV-1 isolates
(reviewed in Stamatatos et al., 2009). A
handful of monoclonal antibodies from
infected individuals had been identified
in the early 1990s (2F5, 2G12, 4E10, andª2009 Elsevier Inc.b12), each of which could prevent infec-
tion in nonhuman primate animal models
(Mascola, 2003). Because each of these
monoclonal antibodies identifies a highly
conserved target of HIV-1 neutralization,
additional broadly neutralizing antibodies
have been intensively sought. Despite
repeated attempts, however, such anti-
bodies have not been forthcoming,
suggesting that appropriate antibody-
producing B cells might be rare.
To address this ‘‘needle in the hay-
stack’’ problem, Burton and colleagues
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Figure 1. Identification of New Broadly Neutralizing Antibodies Is Dependent on Direct Screening for Neutralization
Steps involved in the isolation of new broadly neutralizing antibodies are outlined and involve identification of B cell clones with neutralizing antibody activity and
direct cloning of immunoglobulins.
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nology collaborators Mono-
gram and Theraclone, devel-
oped three technological
advances that allowed the
definition of two new mono-
clonal antibodies, reported
recently (Walker et al., 2009)
(Figure 1). First, it was neces-
sary to identify optimal patient
samples, a task that required
collecting sera and lympho-
cyte samples on hundreds of
HIV-1-infected individuals to
identify a select group who
have broadly neutralizing
serum antibodies. Second,
most isolated B cells do not
actively secrete IgG. Thus, the group
developed methods to stimulate B cells
to proliferate and to secrete IgG. Third,
the group utilized a high-throughput and
small-scale, or microneutralization, assay
that allowed analysis of neutralization
activity against at least three different
HIV-1 isolates. This analysis allowed iden-
tification of the rare B cells that synthe-
sized broadly neutralizing antibodies (the
long-sought needles!). After PCR amplifi-
cation of IgG genes and cloning and
expression of antibodies from these B
cell clones, the identity and activity of
these selected IgGs could be confirmed
and their properties characterized (Walker
et al., 2009).
The most potent antibodies identified
by the analysis, PG9 and PG16, were
derived from the same germline genes
and appeared to be somatically related.
Both PG9 and PG16 displayed only
weak binding to soluble gp140s but tight
binding to cell surface-expressed oligo-
meric gp120/gp41, which presumably
form trimers and give rise to functional
virus spikes. The only previously de-
scribed HIV-1-reactive antibody with a
similar preference for the conformation-
ally intact viral spike is antibody 2909
(Gorny et al., 2005). Like antibody 2909,
antibodies PG9/PG16 recognize an epi-
tope comprised of variable loops V2 and
V3. Indeed, many of the key gp120 resi-
dues that are important for PG9/PG16
recognition are important for 2909 as
well. These similarities suggest that
antibodies PG9/PG16 and antibody
2909 recognize similar epitopes on the
V2/V3 of gp120 (Figure 2). However,
PG9/PG16 recognize a common form of
the epitope, which has an N-linked
glycosylation site at residue 160 in the
V2 region of gp120, whereas antibody
2909 requires a rare form of the epitope,
with a Lys at residue 160. Of interest, anti-
bodies PG9/PG16 and antibody 2909 all
have a heavy chain derived from IgHV3,
so similarities between these antibodies
include not only the recognized epitope,
but also the antibody sequences them-
selves.
Perhaps the most important implica-
tions of the findings relate to vaccine
development. PG9/PG16 neutralize a
diverse spectrum of HIV-1 isolates at
concentrations that were often 10- to
100-fold lower than the other previously
identified broadly neutralizing antibodies.
This raises the hope that protective
levels of neutralizing antibodies might be
achieved by vaccination. The findings
also provide a glimpse into how the
human immune system uses both VDJ
recombination and somatic variation to
increase the breadth of coverage. The
importance of somatic variation to this
process may be one reason that broad
neutralization in infected individuals is
only observed after a number of years
and suggests that a similar lengthy period
of antigen exposure may be needed in
vaccine settings to elicit a diverse neu-
tralizing response. The new antibodies
also highlight current limitations in the
ability of vaccine immunogens, such as
soluble Env gp120 and gp140, to mimic
appropriately the viral spike. Hence,
current Env vaccines are unable to elicit
neutralizing antibodies that are similar to
PG9/PG16. The flip side of this is that
the ability of the PG9/PG16 antibodies to
discriminate soluble gp140s
from more native cell
surface oligomers provides
a means to assess the spike
mimicry of newly designed
vaccine immunogens. In-
deed, an accurate soluble
mimic of the viral spike has
long been sought as a
vaccine immunogen.
The findings by Burton
and colleagues represent
the maiden voyage for
their impressive B cell stimu-
lation and microneutraliza-
tion technologies, and it is
likely that this success will
be followed by others, using
either the same approach or alternative
methods of B cell enrichment, such as
binding and enrichment with structurally
designed ligands (Scheid et al., 2009).
The top 1% of neutralizing sera identified
by their screen of HIV-1-infected individ-
uals display extraordinarily potent and
broad neutralization of HIV-1 (Simek
et al., 2009). This study presents a tanta-
lizing preview of what may follow: addi-
tional monoclonal antibodies that broadly
neutralize HIV-1. The newPG9/PG16 anti-
bodies may herald a new era in B cell
immunogen design, during which addi-
tional knowledge of the molecular targets
of antibody neutralization and a greater
understanding of B cell development
and affinity maturation serve to guide
future efforts in rational AIDS vaccine
design.
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The Drosophila genome encodes three
transcription factors of the nuclear factor-
kappa B (NF-kB) family: Dorsal, Dif, and
Relish, which regulate the expression of
hundreds of stress and immune response
genes, including those encoding antimi-
crobial peptides. They do so upon recog-
nition of bacteria by pattern-recognition
receptors of the peptidoglycan-recogni-
tion protein (PGRP) family, which trigger
the Toll and IMD signaling pathways to
activate Dif and Dorsal or Relish, respec-
tively. The Toll and IMD pathways share
striking similarities with the mammalian
IL-1-R/TLR and TNF-R1 intracellular sig-
naling cascades and represent useful
paradigms to study the regulation of NF-
kB-dependent innate immune signaling
in an in vivo setting (Ferrandon et al.,
2007). The IMD signaling cascade
involves the scaffold protein IMD, which
shares structural homologies with the
mammalian protein RIP1. Upon recruit-
ment to PGRP-LC, IMD triggers the acti-
vation of a signaling cassette involving
the TAB2/TAK1 and IKK complexes via
the adaptor dFADD and the Caspase-8
homolog Dredd. IKK then promotes
Relish phosphorylation and its nuclear
translocation. In parallel, TAB2/TAK1 also
activates the JNK cascade (Figure 1).
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294 Cell Host & Microbe 6, October 22, 2009Stamatatos, L., Morris, L., Burton, D.R., and Mas-
cola, J.R. (2009). Nat. Med. 15, 866–870.
Walker, L.M., Phogat, S.K., Chan-Hui, P.Y., Wag-
ner, D., Phung, P., Goss, J.L., Wrin, T., Simek,
M.D., Fling, S., Mitcham, J.L., et al. (2009).
Science, in press. Published online September 3,
2009. 10.1126/science.1178746.B Signaling by DU
rseille-Luminy (IBDML), UMR 6216 CNRS, Univ
Marseille Cedex 9, France
-mrs.fr
(IMD) signaling cascade regulates the
ammalian TNF-R1 pathway. Theveno
quitin-specific protease (USP) family,
bacteria.
have revealed the central role of the IMD
signaling cascade in the activation of pro-
tective immune responses to septicemia
caused by Gram-negative bacteria (Fer-
randon et al., 2007). More recently, this
cascade has been implicated in the con-
trol of gut immune responses and resident
microbiota-gut mutualism (Ryu et al.,
2006, 2008). In the gut, IMD signaling
activity is fine-tuned by a subtle balance
of positive and negative inputs to promote
immune tolerance to beneficial resident
bacteria while responding robustly to
infection (Lhocine et al., 2008; Zaidman-
Re´my et al., 2006). A few years ago, ubiq-
uitination was reported to be involved
in the activation of IMD signaling (Zhou
et al., 2005). However, the targeted pro-
teins and most of the enzymes respon-
sible for these modifications remained
elusive. In this issue of Cell Host &
Microbe, Thevenon and colleagues now
reveal that modification of the scaffold
protein IMD with K63-linked polyubiquitin
chains is a critical step in the activity of
the signaling cascade (Thevenon et al.,
2009). Moreover, they demonstrate that
dUSP36, a deubiquitinating enzyme (DUB)
of the ubiquitin-specific protease (USP)
family, is an important regulator of this
process, antagonizing the constitutive
IMD signaling that would otherwise be
ª2009 Elsevier Inc.Wei, X., Decker, J.M., Wang, S., Hui, H., Kappes,
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n et al. (2009) reveal how dUSP36,
prevents the constitutive activation
activated by gut-resident bacteria (Fig-
ure 1).
Thevenon et al. (2009) identified
dUSP36, the Drosophila ortholog of
human USP36, in an overexpression
screen aimed at identifying regulators of
host resistance to infection by Pseudo-
monas aeruginosa. Ubiquitous overex-
pression of dUSP36 enhances the
susceptibility of flies to P. aeruginosa
septicemia by antagonizing IMD signaling
activity. The effect of dUSP36 overex-
pression on IMD signaling relies entirely
on its ubiquitin protease activity, since
the expression of a catalytically dead
mutant version of dUSP36 affects neither
IMD signaling transcriptional outputs nor
flies’ resistance to P. aeruginosa septi-
cemia. Next, the authors generated a
loss-of-function mutation of dUSP36.
Such mutation causes an early lethality,
most probably associated with other roles
of dUSP36 in stem cell maintenance
and the regulation of developmental
apoptosis (Buszczak et al., 2009; Ribaya
et al., 2009). The authors elegantly
rescued this lethality by conditional
expression of a wild-type dUSP36 trans-
gene during development to study the
role of dUSP36 at the adult stage. In
parallel, they also used an in vivo-induc-
ible RNAi approach to selectively silence
